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Abstract
Data implicate IL-1 in the altered matrix biology that
characterizes human intervertebral disc (IVD) degeneration. In
the current study we investigated the enzymic mechanism by
which IL-1 induces matrix degradation in degeneration of the
human IVD, and whether the IL-1 inhibitor IL-1 receptor
antagonist (IL-1Ra) will inhibit degradation. A combination of in
situ zymography (ISZ) and immunohistochemistry was used to
examine the effects of IL-1 and IL-1Ra on matrix degradation and
metal-dependent protease (MDP) expression in explants of non-
degenerate and degenerate human IVDs. ISZ employed three
substrates (gelatin, collagen, casein) and different challenges
(IL-1β, IL-1Ra and enzyme inhibitors). Immunohistochemistry
was undertaken for MDPs. In addition, IL-1Ra was introduced
into degenerate IVD explants using genetically engineered
constructs. The novel findings from this study are: IL-1Ra
delivered directly onto explants of degenerate IVDs eliminates
matrix degradation as assessed by multi-substrate ISZ; there is
a direct relationship between matrix degradation assessed by
ISZ and MDP expression defined by immunohistochemistry;
single injections of IVD cells engineered to over-express IL-1Ra
significantly inhibit MDP expression for two weeks. Our findings
show that IL-1 is a key cytokine driving matrix degradation in the
degenerate IVD. Furthermore, IL-1Ra delivered directly or by
gene therapy inhibits IVD matrix degradation. IL-1Ra could be
used therapeutically to inhibit degeneration of the IVD.
Introduction
Chronic low back pain either alone or in association with sci-
atica (CLBP), is a common musculoskeletal disorder causing
considerable population morbidity (6% prevalence) and an
£11 billion pound annual cost to the UK economy through
social and healthcare expenditure and loss of work. Recent
controlled studies have established a causal association
between degeneration of the intervertebral disc (DIVD) and
CLBP [1,2].
Individual intervertebral discs (IVDs) are part of a complex of
interdependent spinal structures known as the 'motion seg-
ment', in which IVDs facilitate movement and maintain optimal
separation and orientation of other elements. This is achieved
by a biomechanical balance between the IVD's two main struc-
tural elements, the nucleus pulposus (NP) and the annulus
fibrosus (AF). Normal NP consists of type II collagen fibres and
proteoglycans, notably aggrecan [3], which form a hydrophilic
molecular complex that generates a swelling pressure suffi-
cient to separate adjacent vertebrae. Excessive swelling is
ADAMTS = a disintegrin and metalloproteinase with thrombospondin motifs; Ad-GFP = adenoviral constructs incorporating green fluorescent protein; 
AF = annulus fibrosus; ANOVA = Analysis of variables; BSIP = broad spectrum inhibitor of proteinases; CcCl = Cesium chloride; CLBP = chronic 
low back pain with or without sciatica; DIVD = degeneration of the intervertebral disc; GFP = green fluorescent protein; IHC = immunohistochemistry; 
IL = interleukin; IL-1Ra = interleukin-1 receptor antagonist; ISZ = in situ zymography; IVD = intervertebral disc; MDP = metal-dependent proteases; 
MMP = matrix metalloproteinase; MOI = Multiplicity of infection; mRNA = messenger ribose nucleic acid; NP = nucleus pulposus; PMSF = phenyl 
methyl sulphonyl fluoride; RNA = ribose nucleic acid; T = thymidine.
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resisted by tension in the type I collagen fibre arrays of the AF.
The balance between swelling of the NP and tension in the AF
ensures optimal separation of adjacent vertebral bodies and
efficient biomechanics of the motion segment.
DIVD is a disorder characterized by loss of hydrophilic matrix
from the NP, leading to reduced vertebral separation, instabil-
ity of the motion segment, microtrauma, and disc bulging [4].
Searches for a cause of loss of matrix molecules through
largely observational studies of enzyme expression have
implicated metal-dependent matrix degrading enzymes (metal-
dependent proteases (MDPs) – matrix metalloproteinases
(MMPs), metalloproteinases with thrombospondin motifs
(ADAMTS)) in matrix degradation in DIVD [3,5-8]. However,
not all data completely support this view [7-9], and direct evi-
dence from intact human tissue is sparse.
Whilst upstream events driving enzyme production are largely
unknown, the cytokine IL-1 has been implicated [10-13]. Sup-
porting evidence from our own laboratory includes: showing
that by comparison with non-degenerate IVD, in DIVD both
isoforms of IL-1 (IL-1α/IL-1β), IL-1 receptor (IL-1R1) and IL-1
converting enzyme are over-expressed [14] without corre-
sponding up-regulation of the natural inhibitor of IL-1, inter-
leukin-1 receptor antagonist (IL-1Ra) [14]; and in monolayer
and three-dimensional alginate culture, IL-1Ra will down-regu-
late expression of MDPs by cells from degenerate IVDs [15].
Inhibiting degenerative processes would be a novel approach
to managing DIVD, were it possible to identify key molecular
targets. In this context an IL-1-driven, MDP-mediated mecha-
nism would be attractive, with inhibitors such as IL-1Ra
already in use in rheumatology [16].
In the current study we have addressed the lack of direct evi-
dence for this mechanism in human tissue, believing this to be
an essential step in translating current laboratory data into clin-
ical applications, by examining the hypothesis 'matrix degrada-
tion in DIVD is inhibited by IL-1Ra'. In addition, recognizing the
difficulties involved in delivering therapeutic agents into
degenerate IVDs, we have investigated the hypothesis 'gene
therapy is a practical way of delivering IL-1Ra into degenerate
IVD'.
We have used in situ zymography (ISZ) to assess matrix deg-
radation. In vivo, enzyme activity is highly regulated at a
number of different levels (for example, gene expression and
translation, proenzyme activation, enzyme-matrix interactions,
endogenous inhibitors, and so on [17]). As such, conventional
approaches (for example, enzyme expression, cells in artificial
matrices, extraction zymography) that cannot account for the
full spectrum of regulatory controls cannot adequately reflect
enzyme activity in vivo. ISZ [18] approximates more closely the
in vivo situation than other techniques and is becoming widely
used in oncology [19,20] and musculoskeletal research
[21,22] for localizing enzyme activity in human and animal tis-
sues. ISZ works only if active, uninhibited enzyme is present,
which means enzyme RNA must have been synthesised, trans-
lated to pro-enzyme and the pro-enzyme activated. Further-
more, the reaction will proceed only if there is less 'inhibitor
potential' than 'enzyme potential', and because the tissue is
intact this will include tissue bound inhibitors.
ISZ is specific for the matrix molecule (for example, type II col-
lagen) but not the enzyme. Conventionally, several matrices
are selected that cover the spectrum of enzyme activity being
investigated. The tissue can be pretreated to examine the
effects of putative stimulators/inhibitors of enzyme activity.
In the experiments described here we have examined enzyme
activity directed at degradation of collagen type II, gelatin and
casein in intact normal and degenerate human AF and NP tis-
sue, both with and without pretreatment with IL-1 and IL-1Ra.
We have also examined the same tissue by immunohistochem-
istry (IHC) for evidence of expression of a limited number of
matrix enzymes that are both expressed in degenerate IVDs
and are active against the ISZ matrices.
Finally, having found that IL-1Ra affects matrix degradation, we
have investigated a novel method that might form the basis of
delivery of IL-1Ra into the human degenerate IVD.
Materials and methods
Experiment 1: ISZ localization of matrix degrading 
activity in normal and degenerate IVDs – the effects of IL-
1, IL-1Ra and inhibitors of matrix degrading enzymes
Source of human IVDs
Non-degenerate and degenerate IVDs were obtained from 18
cadavers within 16 hours of death (Trent Multicenter Research
Ethics Committee – 05/MRE04/03) and 13 live patients (Sal-
ford and Trafford [01/049] and Central Manchester [C/01/
008] Local Research Ethics Committees) (Table 1). All sam-
ples were taken with informed consent of the patient or rela-
tive. Two to four parallel, sagittally orientated tissue slabs
incorporating AF and NP were taken from each case.
Tissue processing and histological assessment
One slab was processed for histology, in situ hybridization and
IHC, using formalin fixation and paraffin embedding [23]. Sam-
ples were checked for orientation and inclusion of AF and NP,
and scored for degree of degeneration using a published his-
tological 12 point scale [24]. IVDs scoring 4 to 8 were graded
'moderately degenerate' and 9 to 12 'severely degenerate'.
Non-radioactive in situ hybridization using a poly T probe for
polyadenylated mRNA tested cell viability [25].
From 30 IVDs, the other slabs were used to generate 3 tissue
blocks measuring 5 × 3 × 3 mm, incorporating AF and NP for
ISZ. From 5 IVDs (score 7 to 8), 3 to 6 5 × 5 × 5 mm blocks
of NP were taken for gene delivery studies (see experiment 3
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Table 1
Details of the individuals and the tissue sources used in these studies (CVA = cerebrovascular accident ["stroke"])
Age (years) and sex Spinal level Score Reason excised/cause of death
Normal tissue: live patients
18 M L4/5 0 Spinal trauma
L5/S1 1
24 M L3/4 1 Spinal trauma
48 F L3/4 1 Spinal reconstruction for metastatic breast cancer
Normal tissue: cadaveric
59 F L3/4 1 Massive pulmonary embolism
52 M L4/5 1 Myocardial infarction
47 M L3/4 1 Road traffic accident
72 M L3/4 1 Myocardial infarction
64 M L5/S1 2 Myocardial infarction
75 F L4/5 2 CVA
47 F L4/5 3 Ovarian cancer
58 M L4/5 3 Myocardial infarct
Degenerate tissue: live patients
51 M L4/5 7 Disc degeneration
60 M L4/5 7 Disc degeneration
25 M L4/5 8 Disc degeneration
45 M L4/5 8 Disc degeneration
48 M L4/5 8 Disc degeneration
73 F L3/4 9 Disc degeneration
61 M L5/S1 9 Disc degeneration
45 F L5/S1 9 Disc degeneration
53 M L4/5 10 Disc degeneration
46 F L4/5 11 Data not available
Degenerate tissue: cadaveric
49 F L4/5 5 Data not available
57 F L4/5 6 Myocardial infarction
64 M L4/5 7 Myocardial infarction
69 M L4/5 8 CVA
47 F L3/4 8 Breast cancer
76 M L4/5 9 CVA
50 M L3/4 9 Myocardial infarction
61 F L5/S1 10 Data not available
28 M L4/5 11 Road traffic accident
59 M L4/5 11 Myocardial infarction
F, female; M, male.
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below) and 2 IVDs from an 18 year old male were used to iso-
late NP cells for these studies as described previously [15].
In situ zymography
Ten non-degenerate (eight cadaveric, two live patient), ten
moderately degenerate (five surgical, five cadaveric), and ten
severely degenerate (five cadaveric, five surgical) IVDs were
studied. One block was incubated for 48 hours at 35°C in
TRIS-HCl buffer, and the other two in buffer supplemented
with IL-1β (10 ng/ml recombinant human IL-1β (R&D Systems,
Abingdon, Oxfordshire, UK)) [15], or IL-1Ra (100 ng/ml (R&D
systems)).
Tissue blocks were snap frozen, and 15 μm tissue sections
were examined for evidence of gelatinase, caseinase and type
II collagenase activity. ISZ was performed as described previ-
ously [21] on 36 randomized serial sections from each block.
Sections were mounted on slides precoated with gel contain-
ing equal quantities of 1% agarose and 1 mg/ml of FITC-
labeled gelatin, casein or bovine type II collagen (Sigma,
Poole, Dorset, UK) (It is not possible to gel aggrecan and so
aggrecanase activity was not tested directly.) Inside a 100%
humidity chamber, 2 randomized serial sections were covered
by a large, self-supporting drop of liquid consisting of either
TRIS-HCl buffer, pH 7.4, alone or supplemented with an
enzyme inhibitor (broad spectrum protease inhibitor (BSIP)
consisting of TRIS buffer containing (from Sigma) 200 μM
phenylmethyl sulphonyl fluoride (PMSF; serine protease inhib-
itor), 1 μM leupeptin (serine/cysteine protease inhibitor), 100μM EDTA (MDP inhibitor), and 1 μM pepstatin (aspartate pro-
tease inhibitor) or specific inhibitors consisting of one compo-
nent only). The zymographic reaction was allowed to proceed
for 48 hours at 35°C, changing the medium 12 hourly.
At 0 and 48 hours, slides were viewed in a fluorescence image
analyzer, the image captured and area of gel digested meas-
ured using semi-automated image analysis.
Experiment 2: localization and semiquantification of 
matrix degrading enzyme expression in sections used 
for ISZ
At the end of each ISZ experiment, sections were removed
from the slides, fixed in formalin and paraffin embedded for
IHC. The thickness of the sections used for ISZ limited the
number of sections reliably available for IHC to three. Based
on previous expression studies, MMPs expressed in the
degenerate IVD and that preferentially degraded the ISZ matri-
ces (MMP3 (caseinase/aggrecanase/gelatinase), MMP7
(gelatinase/aggrecanase), MMP13 (type II collagenase)) were
selected for IHC.
IHC, performed as previously published [5], was used to local-
ize MMP3, MMP 7 and MMP 13 in 3 μm paraffin sections.
Antibodies were from R&D systems. Anti-MMP7 and -13 anti-
bodies were mouse monoclonals and the anti-MMP3 antibody
a goat polyclonal. Chymotrypsin antigen retrieval was required
for anti-MMP7. The presence of bound antibody was dis-
closed using biotinylated rabbit anti-mouse or donkey anti-
goat antibodies in conjunction with a streptavidin, biotin, DAB
(3,3'-diaminobenzidine tetrahydrochloride) system. In both AF
and NP, 100 to 300 cells (determined by sample size and cel-
lularity) were used to assess the percentage of nucleated cells
immunopositive for each enzyme.
Experiment 3: assessment of the effectiveness of a gene 
delivery system in inhibiting MDP expression in 
degenerate human IVDs
Three blocks of NP from two degenerate IVDs and six from
three were encapsulated in Perspex rings [26] and investi-
gated for the effect of IL-1Ra, delivered by genetically engi-
neered NP cells, on immunohistochemical MMP/ADAMTS
expression after 48 hours (five IVDs) and two weeks (three
IVDs).
Adenoviral constructs incorporating green fluorescent protein
(Ad-GFP; control) or IL-1Ra were generated by Cre-lox recom-
bination [15]. Viruses grown in HEK 293 cells were purified
using CsCl density gradient purification. IVD cell monolayers
transfected at an MOI (mean number of viruses per target cell)
of 300 were cultured overnight at 37°C in 5% CO2. Viable
monolayer cells were suspended, centrifuged at 1500 g for 10
minutes and resuspended at a density of 100,000 cells per 20μl.
After 24 hours in standard medium, encapsulated explants
were injected with either 20 μl of medium, or 20 μl of medium
containing transfected cells or untransfected control cells. IL-
1Ra was measured by ELISA. (Transfected cells produced
100 to 200 ng/ml per explant.) After a further 48 hours, 5
blocks, and after 14 days another 3 blocks, were fixed in for-
malin and paraffin embedded.
IHC was used to stain 4 μm sections for MMP1, -3, -7, and -
13 and ADAMTS4. The IHC techniques were as described
above for MMP3, -7 and -13. Monoclonal mouse anti-human
MMP1 antibody was obtained from R&D systems and polyclo-
nal goat anti-human ADAMTS4 from Santa Cruz, Santa Cruz,
California, USA. Chymotrypsin antigen retrieval was required
for anti-MMP1. Positive cells were expressed as a percentage
of all nucleated cells.
Statistical analysis
Between group differences were assessed using a two-tailed
ANOVA analysis.
Results
In situ hybridization
All the tissue used showed evidence of an expected degree of
cell viability. In the normal tissue this was >95% of cells react-
ing for polyadenylated RNA. Because of apoptosis a propor-
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tion of cells in degenerate IVDs will be unreactive; in these
IVDs >70% (range 71% to 94%) of cells were positive.
In situ zymographic studies
Matrix degradation occurred below cell profiles rather than
intercellular matrix.
Cytokine and anti-cytokine effects
ISZ data for untreated and IL-1/IL-1Ra treated tissue are
shown in Figure 1 and illustrated in Figure 2a.
Non-degenerate IVDs
Type II collagenase, gelatinase and caseinase activity were
present in NP and AF. IL-1β increased the degradation area of
all three substrates by four- to ten-fold depending on enzyme
and region of the IVD (greatest, gelatinase in the NP; least,
caseinase in the AF). IL-1Ra eliminated 95% to 100% of activ-
ity of all enzymes in the AF and NP (p < 0.01).
Moderately degenerate IVDs
Enzyme activity was present against all 3 substrates, 4- to 13-
fold higher than in the non-degenerate IVDs, and highest in the
NP. IL-1β increased degradation of all three substrates, but
with the exception of gelatinase activity in the AF (p < 0.05),
this did not reach statistical significance. IL-1Ra eliminated
95% to 100% of all enzyme activity (p < 0.01).
Figure 1
Effects of IL-1 and IL-1 receptor antagonist (IL-1Ra) on the in situ zymography profile of degenerate and non-degenerate intervertebral discs (IVDs)i  (I - )  t  i  sit  zy o ra hy profile of degenerate and non-degenerate intervertebral discs (IVDs). 
The six graphs compare matrix degrading activity in the nucleus pulposus (NP) and annulus fibrosus (AF) for the three substrates in non-degenerate, 
moderately degenerate and severely degenerate IVDs and following treatement with IL-1 and IL-1Ra. The data are expressed in terms of absolute 
area of gel degraded (Y-axis = area degraded (maximum 10% in NP and 2.5% in AF)). Data are expressed as mean + standard error of the mean.
Arthritis Research & Therapy    Vol 9 No 4    Le Maitre et al.
Page 6 of 12
(page number not for citation purposes)
Severely degenerate IVDs
Degradation of all three substrates was greater in severely
degenerate than non-degenerate IVDs (p < 0.01), but lower
than in moderately degenerate IVDs (p < 0.01). The pattern of
IL-1 and IL-1Ra effects was similar to that in moderately
degenerate IVDs, except in the AF, where IL-1Ra decreased
caseinase activity by 85%, gelatinase activity by 65% and col-
lagenase activity by 50%.
Enzyme inhibitors
BSIP eliminated all enzyme activity in every situation. Where
enzyme activity was present, EDTA caused >95% decrease in
all enzyme activity in the NP and AF (Figure 3a), with the
exception of the AF of moderately and severely degenerate
IVDs, where it inhibited all caseinase activity (p < 0.01) but
only 40% of type II collagenase (p < 0.02) and 70% of gelati-
nase (p < 0.02) activity. Here, PMSF caused a 35% reduction
in collagenase and 22% reduction in gelatinase activity
(p < 0.05 for both) and leupeptin a 21% reduction in colla-
genase activity (p < 0.05), indicating serine/cysteine protease
activity in the AF. This is illustrated in Figure 3b, which docu-
ments graphically the effects of IL-1Ra, BSIP, EDTA, PMSF
and leupeptin on collagen type II matrix degradation in the NP
and AF. The other inhibitors had no effect (data not shown).
Cadaveric versus live tissue
There were no statistical differences in any experiment
between cadaveric and surgically excised IVDs matched for
age, sex or degradation score.
Immunohistochemical analysis of treated tissue blocks
Immunohistochemical data are shown in Table 2 and illus-
trated in Figure 2b. Data are only shown for untreated and
IL-1β/IL-1Ra-treated samples as no other treatment affected
enzyme expression.
Non-degenerate tissue
The 3 MMPs were expressed by 1% to 4% of NP cells and
0.3% to 1% of AF cells. Enzyme expression in both regions
increased four- to ten-fold with IL-1 treatment (p < 0.01).
IL-1Ra reduced immunodetectable enzyme expression by at
least 90% for all enzymes in AF and NP (p < 0.02).
Moderately degenerate IVDs
When compared with non-degenerate tissue, cells within
these IVDs showed significantly greater (p < 0.01) innate
expression of all three enzymes. IL-1 increased enzyme
expression generally but only MMP3 in the NP significantly
(p < 0.05), and MMP7/MMP13 (p < 0.05) in the AF. In AF and
NP, IL-1Ra reduced enzyme expression by at least 90%
(p < 0.01).
Severely degenerate IVDs
Expression of MMP3, -7 and -13 was significantly greater than
in non-degenerate NP (p < 0.02) but not the AF. IL-1β
increased and IL-1Ra decreased enzyme expression in a simi-
lar pattern to that in moderately degenerate IVDs.
Correlation of enzyme activity and protein expression
To assess any relationship between matrix degradation (ISZ)
and MDP expression (IHC), scatter plot analyses was per-
formed. These show statistically significant correlations
(p < 0.01) for type II collagenase activity versus MMP13
expression, gelatinase and caseinase activity versus MMP7
expression, and caseinase and gelatinase activity versus
MMP3 expression. Other combinations did not reach statisti-
cal significance.
Figure 2
Images illustrating the histological appearances of in situ zymography (ISZ) and immu ohistochemistry (IHC) in moderately degenerate intervertebral d scs (IVD )
(ISZ) and immunohistochemistry (IHC) in moderately degenerate 
intervertebral discs (IVDs). (a) Photomicrographs taken using the fluo-
rescent microscope. The black rounded areas are regions of matrix 
degradation. There are none of these areas within the right hand image 
of a specimen treated with IL-1 receptor antagonist (IL-1Ra). The out-
lines of cells can just be made out in this image as pale grey ghosts. (b) 
IHC performed on formalin fixed, paraffin embedded tissue derived 
from the ISZ experiments. Matrix metalloproteinase (MMP)3 is seen in 
the cytoplasm of many of the cells in the untreated tissue. It increases 
(non-significantly) after IL-1 treatment and is markedly reduced follow-
ing IL-1Ra treatment (right-hand image). In this image the nuclei of the 
nucleus pulposus (NP) cells can be seen where they have taken up the 
counterstain, which contrasts with the darker cytoplasmic staining of 
IHC reaction product for MMP3 in the left and center images.
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Figure 3
Effects of enzyme inhibitors on matrix degradationi i i  tri  r ti . All results are expressed as a percentage of the mean of the measured area of degradation of the 
untreated samples. All data given as mean ± standard error of the mean. (a) Comparison of the effects of IL-1 receptor antagonist (IL-1Ra), broad 
spectrum inhibitor of proteases (BSIP) and EDTA on degradation of the three matrices in non-degenerate, moderately degenerate and severely 
degenerate intervertebral discs (IVDs). In the nucleus pulposus (NP) all the inhibitors effectively eliminate enzyme activity. In the annulus fibrosus 
(AF) of moderately degenerate IVDs, BSIP and IL-1Ra eliminate enzyme activity but EDTA only reduces type II collagenase and gelatinase activity. In 
the AF of severely degenerate IVDs, BSIP eliminates collagenase and gelatinase activities, but both IL-1Ra and EDTA only reduce them. (b) Com-
parison of the effects in AF and NP of moderately degenerate IVDs of all the inhibitors employed in this study (IL-1Ra, BSIP, EDTA, phenyl methyl 
sulphonyl fluoride (PMSF) and leupeptin) to show differences in the enzyme subgroups involved. The key finding is in the AF, where IL-1Ra elimi-
nated all enzyme activity but EDTA did not, indicating that the enzymes involved were driven by IL-1 but were not metal-dependent proteases 
(MDPs). By contrast with the NP, PMSF and leupeptin did reduce enzyme activity, indicating that those IL-1 driven, non-MDP enzymes were serine/
cysteine proteases.
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Effects of IL-1Ra gene therapy on enzyme expression
The effects of IL-1Ra delivered by transfected cells on MMP/
ADAMTS expression in moderately degenerate NP are shown
in Figure 4 (Ad-GFP data are not shown as they are identical
to untransfected cells).
Medium had no effect on enzyme expression. Injection of
untransfected/Ad-GFP transfected NP cells into degenerate
NP explants led to a reduction in the percentage of cells
expressing all enzymes at 48 hours (statistically significant for
only MMP3 (p < 0.05) and ADAMTS4 (p < 0.05)) and 2
weeks (significant for MMP3 only (p < 0.05)).
Injection of cells expressing IL-1Ra caused a dramatic and sta-
tistically significant (p < 0.01) reduction in expression of all
enzymes at 48 hours. This was sustained for two weeks after
injection with no statistical difference in expression over that
period.
Discussion
In DIVD, reduction in vertebral separation secondary to
enzyme-mediated matrix loss has been causally linked to
CLBP, a debilitating and economically important disorder
[27,28] for which current treatments have only limited suc-
cess. Understanding the molecular mechanisms leading to
matrix degradation is a key step in designing novel treatments
for degeneration [29].
It is known from expression studies that in degenerate human
IVDs, key MDPs, notably MMP1, -3, -7 and -13, and
ADAMTS4, are upregulated [5,30,31]. In three-dimensional
alginate culture, IL-1β upregulates expression of these
enzymes by IVD cells [15]. In non-degenerate IVD, cells
express IL-1α/β [14], expression matched by that of IL-1Ra. In
degeneration, however, IL-1α/β are upregulated without
increased IL-1Ra. Co-culture of cells from degenerate IVD
with cells engineered to over-express IL-1Ra inhibits IL-1 syn-
thesis [15]. These and similar data derived from human gene/
gene product expression, experimental animal and cell-based
in vitro studies form the basis of proposed mechanism for
Table 2
Percentage of cells expressing IHC detectable MMP3, -7 or -13 following incubation of tissue in standard medium, or medium 
supplemented with IL-1 or IL-1Ra for 48 hours
MMP3 MMP7 MMP13
Mean 
(percent)
SEM Mean 
(percent)
SEM Mean 
(percent)
SEM
Non-degenerate NP Untreated 0.9 1.0 4.2 2.1 2.7 0.9
IL-1 6.5 1.2 35.8 7.6 11.3 5.2
IL-1Ra 0 0.0 0.2 0.1 0.2 0.1
AF Untreated 0.3 0.2 0.4 0.2 0.3 0.2
IL-1 1.2 0.5 1.9 0.9 1.5 0.5
IL-1Ra 0.0 0.0 0.2 0.1 0.0 0.0
Moderately degenerate NP Untreated 10.2 4.1 72.6 10.9 31.9 7.7
IL-1 14.1 5.6 83.4 10.1 38.2 10.7
IL-1Ra 0.0 0.0 3.3 1.2 2.7 1.1
AF Untreated 1.9 0.9 3.5 1.1 1.0 0.4
IL-1 2.8 1.4 5.1 0.9 1.5 0.5
IL-1Ra 0.2 0.1 0.2 0.1 0.1 0.1
Severely degenerate NP Untreated 3.6 1.2 17.9 6.0 16.2 7.2
IL-1 6.5 3.1 19.4 6.5 19.9 6.3
IL-1Ra 0.2 0.1 2.2 1.1 2.1 1.2
AF Untreated 2.0 0.4 0.9 0.4 0.2 0.1
IL-1 2.8 0.7 1.1 0.2 2.3 0.7
IL-1Ra 0.2 0.1 0.2 0.1 0.1 0.0
AF, annulus fibrosus; IHC, immunohistochemistry; IL-1Ra, interleukin-1 receptor antagonist; MMP, matrix metalloproteinase; NP, nucleus 
pulposus; SEM, standard error of the mean.
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matrix loss in the degenerate IVD in which matrix degradation
is driven by IL-1 and mediated through MDPs. As the biology
of MDP and IL-1 are well known and naturally occurring
inhibitors (TIMPs, IL-1Ra) are already used to treat joint
disease, MDP and IL-1 are attractive therapeutic molecular
targets in the setting of degeneration of the IVD and disco-
genic low back pain [16].
In the current study we have examined the evidence for the
existence of this mechanism in intact human IVD tissue and the
potential for MDP inhibitors and IL-1Ra to reverse the disease
process. The novel data we are reporting are: direct evidence
for MDPs being the major enzymes involved in matrix degrada-
tion in the NP, but serine/cysteine proteases having an impor-
tant role with MDPs in the AF; IL-1Ra and EDTA inhibiting type
II collagnease, caseinase and gelatinase activity in the NP;
EDTA having limited effects on matrix degrading activity in the
AF whereas IL-1Ra almost completely eliminates it; matrix
degrading activity correlates with MDP expression in human
IVD; IL-1Ra delivered by gene therapy can significantly dimin-
ish MDP expression for sustained periods.
Our data show that MDPs are the major functional enzyme
group in non-degenerate and degenerate IVD. Although this is
the first study to demonstrate this directly, associations
between enzyme expression and the extent of degenerative
changes [5,6,32] or duration of symptoms [33] have indicated
this should be the case. Expression studies of MMP1, -2, -3, -
7, -8, -9, -13 and -19, and ADAMTS 4 and -5 in DIVD
[5,6,8,14,30-39] have particularly implicated MMP1, -3, -7
and -13, and ADAMTS4 in matrix degradation.
Most previous studies of human IVD have studied herniated
tissue; however, herniated tissue is not believed to be the seat
of the processes of degeneration. By selecting cases for study
in which whole IVDs have been excised and by using quantita-
tive image analysis, we have been able to investigate disease
mechanisms within those IVD components primarily affected
by the processes of degeneration, localize matrix degrading
activity within the NP and AF, and correlate matrix degrading
activity with enzyme expression. This has shown that MDPs
are the key mediators of matrix degradation in the NP, but that
matrix degradation in the AF is mediated by both MDPs and
serine/cysteine proteases. In this context it is of interest that
the serine/cysteine proteases cathepsins G and L [7,9] have
been identified in human AF. Our data have also shown that,
in keeping with these data, the MDP inhibitor EDTA eliminated
all enzyme activity in the NP, but only part of that in the AF. By
contrast, IL-1Ra gave ≥95% inhibition of enzyme activity in
both. Furthermore, it inhibited enzyme expression when EDTA
did not, suggesting IL-1 would be a better clinical target than
MDP in the management of DIVD.
The first evidence that IL-1 might be involved in matrix degre-
dation in DIVD came in 1988 from in vitro experiments employ-
ing rabbit AF cells [40]. In 1997, a ground-breaking study [36]
extended these data into human IVD but did not fully localize
enzymes within the IVD, relate enzyme activity to expression or
show the inhibitory potential of IL-1Ra.
Demonstrating that inhibitors of IL-1Ra almost completely
eliminate matrix degrading activity places IL-1 as a key regula-
tor of matrix degradation in DIVD. This would also explain why
IL-1 has greater expression in those IVDs demonstrated clini-
cally to be the source of CLBP [14,41,42] and the links
between back pain and possession of IL-1aT889, IL-
1RNA1812, and IL-1bT3954 alleles [43-45]. That IL-1 upreg-
ulates its own expression [14] is reflected in the data (Figure
4). These show IL-1Ra quickly extinguishes MDP expression
but, in the absence of IL-1Ra, IL-1-driven MDP expression is
Figure 4
The effect of IL-1 receptor antagonist (IL-1Ra)-transfected cells on matrix me alloproteinase (MMP) a d a disintegrin and m talloprotein-as with thromb spondin mo ifs (ADAMTS) expression in m derately degenera e interv rtebral discs (IV s)
matrix metalloproteinase (MMP) and a disintegrin and metalloprotein-
ase with thrombospondin motifs (ADAMTS) expression in moderately 
degenerate intervertebral discs (IVDs). The graphs show the effects of 
medium alone, untransfected cells and cells transfected with IL-1Ra on 
the proportion of nucleus pulposus (NP) cells expressing the various 
enzymes by NP cells in human IVD explants at 48 hours and 14 days 
after injection of medium, medium containing non-transfected cells and 
medium containing transfected cells. Data expressed as mean percent 
+ standard error of the mean.
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maintained even in prolonged tissue culture outside the dis-
ease context of the spine. Breaking the auto-stimulation of IL-
1 production could be key to inhibiting progression of
degeneration.
Probing IVD samples with IHC and ISZ has enabled the
degrading activity of specific substrates to be related to
expression of particular MMPs. We have shown a statistically
significant relationship between these two variables. This
proved important in the last part of this study. Maintaining ade-
quate tissue levels of IL-1Ra in IVDs could be problematic. The
avascular IVD does not lend itself to delivery of drugs/biomo-
lecular regulators through the circulation, nor is repeated
direct injection practical. To identify and test a suitable method
for delivering IL-1Ra long-term to the IVD, we have explored
the use of cells engineered to over-express IL-1Ra. It was
hypothesized in 1997 [46] that gene therapy might be an
effective method for delivering disease modifying biologicals
to the IVD, but its use has not been previously reported in
human IVD tissue. The 100 to 200 ng/ml of IL-1Ra produced
by transfected cells significantly decreased the proportion of
cells expressing 5 key degradative enzymes 48 hours after
injection of the cells, an effect sustained for 2 weeks without
evidence of reduced efficacy.
Injection of untransfected and Ad-GFP transfected NP cells
appeared to have some effect on enzyme expression. We have
previously shown that untransfected cells secrete picogram
quantities of IL-1Ra, which could account for some of the
changes [15]. However, it is more likely that this is an effect of
the method used to assess therapeutic effectiveness, the
introduced cells contributing to the total cell pool, but not the
enzyme immunoreactive population.
To the best of our knowledge this is the first published evi-
dence that gene therapy delivered into human IVD explants
can change the molecular mechanisms underlying degenera-
tion. However, many problems still need to be addressed
before this can be a practical proposition, key amongst which
are ensuring that transfected cells can continue to synthesize
active product within the environment of the degenerate
human IVD [47]. Thus, whilst experimental data have shown
that direct injection of viral vector into normal rabbit IVDs leads
to synthesis of gene product and increased production of
proteoglycans [48], the increased nutrient and oxygen transfer
into IVD tissue, the cytokine and eicosanoid load and the
growth factor environment of normal animal IVDs are markedly
different to those of degenerate human IVDs. By using intact
human IVDs and controlled culture conditions we have begun
to address this by reproducing the in vivo situation more
closely than has been possible previously.
Conclusion
This study has built on previous, largely observational data
implicating IL-1 in the matrix degradation that characterizes
degeneration of the IVD. Specifically, we have shown for the
first time that: native cells in intact IVD tissue produce gelatin,
casein and type II collagen degrading enzymes; IL-1 delivered
to non-degenerate IVDs will induce expression of these
enzymes; and IL-1Ra delivered directly to explants of degener-
ate IVDs will almost completely eliminate this enzyme activity.
A further key and novel observation has been to show that the
expression of specific matrix degrading enzymes is propor-
tional to matrix degrading activity.
Finally, we have shown that IL-1Ra can be effectively delivered
to degenerate IVDs by injecting cells genetically engineered to
overexpress IL-1Ra into IVD tissue, where it will significantly
inhibit expression of enzymes implicated in degradation of the
IVD. Such an approach applied in vivo could form the basis
either of a therapy for preventing matrix loss in early degener-
ation or in preparing the diseased IVD for tissue engineering
or regenerative medicine strategies designed to restore a nor-
mal matrix [49,50].
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
CLM performed the gene delivery studies and generated and
analyzed the data from these experiments. JAH together with
AJF conceived the study, participated in its design, co-ordina-
tion, analysis and interpretation, and helped to draft the manu-
script. AJF together with JAH developed the ISZ techniques,
performed and analyzed the ISZ studies, participated in the
design of the overall study and were responsible for producing
the final manuscript. All authors read and approved the final
manuscript.
Acknowledgements
The work was undertaken in the Human Tissue Profiling Laboratories of 
the School of Clinical and Laboratory Sciences, with funding from ARC 
(ICAC grant F0551), MRC (Cooperative Group Grant G9900933) and 
the joint Research Councils (MRC, BBSRC, EPSRC) UK Centre for Tis-
sue Engineering (34/TIE 13617), Wellcome Trust (SHoWCaSE grants 
057601/Z/99, 063022/Z/0S) and the AO Foundation.
We thank our surgical colleagues Mr J O'Brien, Mr R Ross, and Mr A 
Kozielokowski for supplying the human tissue and the National Blood 
Service for facilitating timely retrieval of cadaveric tissue. Mrs P Baird 
and Mrs S Moseley undertook much of the technical work.
References
1. Pye SR, Reid DM, Smith R, Adams JE, Nelson K, Silman AJ, O'Neill
TW: Radiographic features of lumbar disc degeneration and
self-reported back pain.  J Rheumatol 2004, 31:753-758.
2. MacGregor AJ, Andrew T, Sambrook PN, Spector TD: Structural,
psychological, and genetic influences on low back and neck
pain: a study of adult female twins.  Arthritis Rheum 2004,
51:160-167.
3. Goupille P, Jayson MIV, Valat JP, Freemont AJ: Matrix metallopro-
teinases: the clue to intervertebral disc degeneration?  Spine
1998, 23:1612-1626.
4. Errico TJ: Why a mechanical disc?  Spine J 2004, 4:151S-157S.
Available online http://arthritis-research.com/content/9/4/R83
Page 11 of 12
(page number not for citation purposes)
5. Le Maitre CL, Freemont AJ, Hoyland JA: Localization of degrada-
tive enzymes and their inhibitors in the degenerate human
intervertebral disc.  J Pathol 2004, 204:47-54.
6. Weiler C, Nerlich AG, Zipperer J, Bachmeier BE, Boos N: 2002
SSE Award Competition in Basic Science: expression of major
matrix metalloproteinases is associated with intervertebral
disc degradation and resorption.  Eur Spine J 2002,
11:308-320.
7. Konttinen YT, Kaapa E, Hukkanen M, Gu XH, Takagi M, Santavirta
S, Alaranta H, Li TF, Suda A: Cathepsin G in degenerating and
healthy discal tissue.  Clin Exp Rheumatol 1999, 17:197-204.
8. Roberts S, Caterson B, Menage J, Evans EH, Jaffray DC, Eisen-
stein SM: Matrix metalloproteinases and aggrecanase: their
role in disorders of the human intervertebral disc.  Spine 2000,
25:3005-3013.
9. Ariga K, Yonenobu K, Nakase T, Kaneko M, Okuda S, Uchiyama Y,
Yoshikawa H, et al.: Localization of cathepsins D, K, and L in
degenerated human intervertebral discs.  Spine 2001,
26:2666-2672.
10. Elfervig MK, Minchew JT, Francke E, Tsuzaki M, Banes AJ: IL-
1beta sensitizes intervertebral disc annulus cells to fluid-
induced shear stress.  J Cell Biochem 2001, 82:290-298.
11. Ahn SH, Cho YW, Ahn MW, Jang SH, Sohn YK, Kim HS: mRNA
expression of cytokines and chemokines in herniated lumbar
intervertebral discs.  Spine 2002, 27:911-917.
12. Shen B, Melrose J, Ghosh P, Taylor F: Induction of matrix metal-
loproteinase-2 and -3 activity in ovine nucleus pulposus cells
grown in three-dimensional agarose gel culture by interleukin-
1beta: a potential pathway of disc degeneration.  Eur Spine J
2003, 12:66-75.
13. Jimbo K, Park JS, Yokosuka K, Sato K, Nagata K: Positive feed-
back loop of interleukin-1beta upregulating production of
inflammatory mediators in human intervertebral disc cells in
vitro.  J Neurosurg Spine 2005, 2:589-595.
14. Le Maitre CL, Freemont AJ, Hoyland JA: The role of interleukin-1
in the pathogenesis of human intervertebral disc
degeneration.  Arthritis Res Ther 2005, 7:R732-745.
15. Le Maitre CL, Freemont AJ, Hoyland JA: A preliminary in vitro
study into the use of IL-1Ra gene therapy for the inhibition of
intervertebral disc degeneration.  Int J Exp Pathol 2006,
87:17-28.
16. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR,
Emery P, Keystone EC, Schiff MH, van Riel PL, Weinblatt ME, et
al.: Updated consensus statement on biological agents for the
treatment of rheumatic diseases, 2006.  Ann Rheum Dis 2006,
65(Suppl 3):iii2-15.
17. Cawston TF, Billington CF, Cleaver C, Elliott S, Hui W, Koshy P,
Shingleton B, Rowan A: The regulation of MMPs and TIMPs in
cartilage turnover.  Ann NY Acad Sci 1999, 878:120-129.
18. Snoek-van Beurden PA, Von den Hoff JW: Zymographic tech-
niques for the analysis of matrix metalloproteinases and their
inhibitors.  Biotechniques 2005, 38:73-83.
19. Stuelten CH, DaCosta P, Byfield S, Arany PR, Karpova TS, Stetler-
Stevenson WG, Roberts AB: Breast cancer cells induce stromal
fibroblasts to express MMP-9 via secretion of TNF-alpha and
TGF-beta.  J Cell Sci 2005, 118:2143-2153.
20. Zhao JX, Yang LP, Wang YF, Qin LP, Liu DQ, Bai CX, Nan X, Shi
SS, Pei XJ: Gelatinolytic activity of matrix metalloproteinase-2
and matrix metalloproteinase-9 in rat brain after implantation
of 9L rat glioma cells.  Eur J Neurol 2007, 14:510-516.
21. Freemont AJ, Byers RJ, Taiwo YO, Hoyland JA: In situ zymo-
graphic localisation of type II collagen degrading activity in
osteoarthritic human articular cartilage.  Ann Rheum Dis 1999,
58:357-365.
22. Sakuraba I, Hatakeyama J, Hatakeyama Y, Takahashi I, Mayanagi
H, Sasano Y: The MMP activity in developing rat molar roots
and incisors demonstrated by in situ zymography.  J Mol Histol
2006, 37:87-93.
23. Cotton SA, Herrick AL, Jayson MIV, Freemont AJ: Endothelial
expression of nitric oxide synthases and nitrotyrosine in sys-
temic sclerosis skin.  J Pathol 1999, 189:273-278.
24. Sive JI, Baird P, Jeziorska M, Watkins A, Hoyland JA, Freemont AJ:
Expression of chondrocyte markers by cells of normal and
degenerate intervertebral discs.  Mol Pathol 2000, 55:91-97.
25. Freemont AJ, Hampson VJ, Tilman R, Goupille P, Taiwo Y, Hoyland
JA: Gene expression of matrix metalloproteinases 1, 3, and 9
by chondrocytes in osteoarthritic human knee articular carti-
lage is zone and grade specific.  Ann Rheum Dis 1997,
56:542-549.
26. Le Maitre CL, Hoyland JA, Freemont AJ: Studies of human
intervertebral disc cell function in a constrained in vitro tissue
culture system.  Spine 2004, 29:1187-1195.
27. Pai S, Sundaram LJ: Low back pain: an economic assessment
in the United States.  Orthop Clin North Am 2004, 35:1-5.
28. Maniadakis N, Gray A: The economic burden of back pain in the
UK.  Pain 2000, 84:95-103.
29. Lotz JC, Kim AJ: Disc regeneration: why, when, and how.  Neu-
rosurg Clin N Am 2005, 16:657-663.
30. Le Maitre CL, Freemont AJ, Hoyland JA: Human disc degenera-
tion is associated with increased MMP 7 expression.  Biotech
Histochem 2006, 81:125-131.
31. Anderson DG, Izzo MW, Hall DJ, Vaccaro AR, Hilibrand A, Arnold
W, Tuan RS, Albert TJ: Comparative gene expression profiling
of normal and degenerative discs: analysis of a rabbit annular
laceration model.  Spine 2002, 27:1291-1296.
32. Crean JK, Roberts S, Jaffray DC, Eisenstein SM, Duance VC:
Matrix metalloproteinases in the human intervertebral disc:
role in disc degeneration and scoliosis.  Spine 1997,
22:2877-2884.
33. Kozaci LD, Guner A, Oktay G, Guner G: Alterations in biochem-
ical components of extracellular matrix in intervertebral disc
herniation: role of MMP-2 and TIMP-2 in type II collagen loss.
Cell Biochem Funct 2006, 24:431-436.
34. Haro H, Komori H, Kato T, Hara Y, Tagawa M, Shinomiya N, Spen-
gler DM: Experimental studies on the effects of recombinant
human matrix metalloproteinases on herniated disc tissues –
how to facilitate the natural resorption process of herniated
discs.  J Orthop Res 2005, 23:412-419.
35. Furusawa N, Baba H, Miyoshi N, Maezawa Y, Uchida K, Kokubo Y,
Fukuda M: Herniation of cervical intervertebral disc: immuno-
histochemical examination and measurement of nitric oxide
production.  Spine 2001, 26:1110-1116.
36. Kang JD, Stefanovic-Racic M, McIntyre LA, Georgescu HI, Evans
CH: Toward a biochemical understanding of human interver-
tebral disc degeneration and herniation. Contributions of nitric
oxide, interleukins, prostaglandin E2, and matrix
metalloproteinases.  Spine 1997, 22:1065-1073.
37. Gruber HE, Ingram JA, Hanley EN: Immunolocalization of MMP-
19 in the human intervertebral disc: implications for disc aging
and degeneration.  Biotech Histochem 2005, 80:157-162.
38. Haro H, Shinomiya K, Murakami S, Spengler DM: Up-regulated
expression of matrilysin and neutrophil collagenase in human
herniated discs.  J Spinal Disord 1999, 12:245-249.
39. Nemoto O, Yamagishi M, Yamada H, Kikuchi T, Takaishi H: Matrix
metalloproteinase-3 production by human degenerated
intervertebral disc.  J Spinal Disord 1997, 10:493-498.
40. Shinmei M, Kikuchi T, Yamagishi M, Shimomura Y: The role of
interleukin-1 on proteoglycan metabolism of rabbit annulus
fibrosus cells cultured in vitro.  Spine 1988, 13:1284-1290.
41. Freemont AJ, Watkins A, Le Maitre CL, Baird P, Jeziorska M, Knight
MT, Ross ER, O'Brien JP, Hoyland JA: Nerve growth factor
expression and innervation of the painful intervertebral disc.  J
Pathol 2002, 197:286-292.
42. Le Maitre CL, Richardson SM, Baird P, Freemont AJ, Hoyland JA:
Expression of receptors for putative anabolic growth factors in
human intervertebral disc: implications for repair and regener-
ation of the disc.  J Pathol 2005, 207:445-452.
43. Solovieva S, Lohiniva J, Leino-Arjas P, Raininko R, Luoma K, Ala-
Kokko L, Riihimaki H: Intervertebral disc degeneration in rela-
tion to the COL9A3 and the IL-1ss gene polymorphisms.  Eur
Spine J 2006, 15:613-619.
44. Solovieva S, Kouhia S, Leino-Arjas P, Ala-Kokko L, Luoma K,
Raininko R, Saarela J, Riihimaki H: Interleukin 1 polymorphisms
and intervertebral disc degeneration.  Epidemiology 2004,
15:626-633.
45. Solovieva S, Leino-Arjas P, Saarela J, Luoma K, Raininko R, Riihi-
maki H: Possible association of interleukin 1 gene locus poly-
morphisms with low back pain.  Pain 2004, 109:8-19.
46. Wehling P, Schulitz KP, Robbins PD, Evans CH, Reinecke JA:
Transfer of genes to chondrocytic cells of the lumbar spine.
Proposal for a treatment strategy of spinal disorders by local
gene therapy.  Spine 1997, 22:1092-1097.
Arthritis Research & Therapy    Vol 9 No 4    Le Maitre et al.
Page 12 of 12
(page number not for citation purposes)
47. Paesold G, Nerlich AG, Boos N: Biological treatment strategies
for disc degeneration: potentials and shortcomings.  Eur Spine
J 2007, 16:447-468.
48. Nishida K, Kang JD, Gilbertson LG, Moon S-H, Suh J-K, Vogt M,
Robbins PD, Evans CH: Modulation of the biologic activity of
the rabbit intervertebral disc by gene therapy: an in vivo study
of adenovirus-mediated transfer of the human transforming
growth factor beta 1 encoding gene.  Spine 1999,
24:2419-2425.
49. Di Martino A, Vaccaro AR, Lee JY, Denaro V, Lim MR: Nucleus
pulposus replacement: basic science and indications for clini-
cal use.  Spine 2005, 30(16 Suppl):S16-22.
50. Richardson SM, Walker RV, Parker S, Rhodes NP, Hunt JA, Free-
mont AJ, Hoyland JA: Intervertebral disc cell-mediated mesen-
chymal stem cell differentiation.  Stem Cells 2006, 24:707-716.
